

2021 VIRTUAL

# SMA CLINICAL CARE SESSION

## CME INFORMATION FOR THE CLINICAL CARE SESSION ONLY

The University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP) and Cure SMA gratefully acknowledge the educational grants provided by Genentech and Novartis Gene Therapies.

### **Target Audience**

Healthcare providers who diagnose and care for people with SMA, including physicians, nurse practitioners, physician assistants and nurses, pediatric and adult specialists including neurologists, pulmonologists, rehabilitation medicine, genetics, orthopedic surgery, palliative care, physical and occupational therapists, speech and language pathologists, pharmacists, nutritionists, genetic counselors, social workers, respiratory therapists, and trainees in the above disciplines.

### **Educational Objectives**

*After completing this activity, the participant should be better able to:*

1. Demonstrate knowledge of multidisciplinary team roles and responsibilities in care management to optimize SMA outcomes.
2. Describe the existing and evolving treatment options for patients with SMA.
3. Describe the impact of new treatments on the SMA phenotype.
4. Analyze the treatment options for management of infants with SMA identified by SMA newborn screening.
5. Demonstrate knowledge of the risk for mental health complications of SMA.
6. Describe the application of mental health screening tools for SMA outpatient use.

## ACCREDITATION STATEMENT



JOINTLY ACCREDITED PROVIDER™  
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by the University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP) and Cure SMA. The University of Wisconsin–Madison ICEP is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

## CREDIT DESIGNATION STATEMENTS

### **American Medical Association (AMA)**

The University of Wisconsin–Madison ICEP designates this live activity for a maximum of 5.5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



**American Board of Pediatrics:** Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 5.5 MOC points in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.



**American Board of Internal Medicine:** Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.



**American Academy of Physician Assistants (AAPA):** The University of Wisconsin–Madison ICEP has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 5.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

#### **American Nurses Credentialing Center (ANCC)**

The University of Wisconsin–Madison ICEP designates this live activity for a maximum of 5.5 ANCC contact hours.

#### **Accreditation Council for Pharmacy Education (ACPE)**

The University of Wisconsin–Madison ICEP designates this knowledge-based activity for a maximum of 5.5 hours/0.55 CEUs of CPE credit. Credit can be earned by documented attendance and by successfully completing the assessment. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.

Universal Activity Number (UAN) JA0000358-9999-21-100-L01-P, 5.5 hours/0.55 CEUs



**American Psychological Association (APA):** Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs.



#### **ASWB Approved Continuing Education (ACE) Social Work Credit:**

As a Jointly Accredited Organization, the University of Wisconsin–Madison ICEP is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. The University of Wisconsin–Madison ICEP maintains responsibility for this course. Social workers completing this course receive 5.5 live continuing education credits.

## Wisconsin Physical Therapy Association (WPTA)

This activity has been approved by the APTA Wisconsin for 5.00 credits.

## Wisconsin Occupational Therapy Association (WOTA)

This activity has been approved by WOTA for 5 credits.

## Continuing Education Units

The University of Wisconsin–Madison ICEP, as a member of the University Professional & Continuing Education Association (UPCEA), authorizes this program for .55 continuing education units (CEUs) or 5.5 hours.

## National Society of Genetic Counselors

This event has been submitted to the National Society of Genetic Counselors (NSGC) for approval of Category 1 CEUs. The American Board of Genetic Counseling (ABGC) accepts CEUs approved by NSGC for purposes of recertification. Approval for the requested CEUs and Contact Hours is currently pending.

---

## FACULTY AND SPONSOR DISCLOSURES

It is the policy of the University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP) to identify, mitigate and disclose all relevant financial relationships with ineligible companies\* held by the speakers/presenters, authors, planners, and other persons who may influence content of this accredited continuing education (CE). In addition, speakers, presenters and authors must disclose any planned discussion of unlabeled/unapproved uses of drugs or devices during their presentation. For this accredited continuing education activity all relevant financial relationships have been mitigated and detailed disclosures are listed below.

NAME	ROLE(S)	FINANCIAL RELATIONSHIPS DISCLOSURE	DISCUSSION OF UNLABELED/ UNAPPROVED USES OF DRUGS/DEVICES IN PRESENTATION?
Kapil Arya, MBBS	Presenter	No relevant relationships with ineligible companies to disclose	No
Mei Baker, MD	Presenter	No relevant relationships with ineligible companies to disclose	No
Vanessa Battista, RN, MS	Planner, Presenter	AveXis; Biogen; Novartis; PTC Therapeutics, Inc. <b>(All Contractor)</b>	No
William Bell, PharmD, MBA	Planner	No relevant relationships with ineligible companies to disclose	N/A
Lisa Belter, MPH	Presenter	No relevant relationships with ineligible companies to disclose	No
John Brandsema, MD	Planner, Presenter	Alexion Pharmaceuticals; Biogen; Catabasis; CSL Behring; FibroGen; Novartis; PTC Therapeutics, Inc.; Pfizer; Sarepta Therapeutics, Inc.; Summit, WaVe <b>(All Grant)</b> ; Audentes; Biogen Idec; Cytokinetics; Genentech; Momenta Pharmaceuticals, Inc.; Novartis Pharma; NS Pharma; PTC Therapeutics, Inc.; Sarepta Therapeutics, Inc.; Scholar Rock; WaVe <b>(All Contractor)</b>	No
Karlla Brigatti, MS, CGC	Presenter	Biogen, Inc.; Novartis <b>(Grant)</b> ; Novartis <b>(Contractor)</b>	No
Jin Yun Chen, MS, CGC	Planner	No relevant relationships with ineligible companies to disclose	N/A
Thomas Crawford, MD	Planner, Presenter	Biogen, Inc.; Genentech USA, Inc.; Sarepta Therapeutics, Inc.; Scholar Rock <b>(All Contractor)</b>	No
Arlene D'Silva, PhD	Presenter	No relevant relationships with ineligible companies to disclose	No
Paul Drake, MD	Presenter	No relevant relationships with ineligible companies to disclose	No
Bakri Elsheikh, MD	Planner, Presenter	Biogen <b>(Contractor and Grant)</b> ; Genentech <b>(Contractor)</b>	No
Al Freedman, PhD	Planner, Presenter	Genentech; Novartis <b>(Both Contractor)</b>	No
Melissa Gibbons, MS, CGS	Planner, Presenter	Biogen; Novartis <b>(Both Grant)</b>	No
Jennifer Hubbell, BS	Planner	No relevant relationships with ineligible companies to disclose	No
Becky Hurst-Davis, MS, RD	Planner	No relevant relationships with ineligible companies to disclose	N/A
Brian Jackson, MD, MA	Presenter	No relevant relationships with ineligible companies to disclose	No
Chamindra Konersman, MD	Planner	Biogen, Inc.; Novartis Pharma; Sarepta Therapeutics, Inc. <b>(All Contractor)</b>	N/A

Richard Kravitz, MD	Planner	AveXis; Biogen, Inc.; Santhera <b>(All Contractor)</b>	N/A
Kristin Krosschell, PT, DPT	Planner	ASPA Therapeutics; Biogen; Genentech; Novartis; <b>(All Contractor)</b> ; Biogen <b>(Grant)</b>	N/A
Oren Kupfer, MD	Planner	No relevant relationships with ineligible companies to disclose	N/A
Cathy Means, MS	Planner	No relevant relationships with ineligible companies to disclose	N/A
Jacqueline Montes, PT, EdD	Presenter	Biogen, Inc.; F. Hoffmann-LaRoche; Genentech USA, Inc.; Sarepta Therapeutics, Inc.; Scholar Rock <b>(All Contractor)</b>	No
Meghan Moore, PT, DPT	Presenter	Biogen, Inc.; Genentech <b>(Both Contractor)</b>	No
Pamela Mosher, MD	Presenter	No relevant relationships with ineligible companies to disclose	No
Diane Murrell, LCSW	Planner, Presenter	No relevant relationships with ineligible companies to disclose	No
Leslie Nelson	Planner	Avexis; Biogen, Inc.; F. Hoffmann-La Roche; Genentech; Novartis; Scholar Rock <b>(All Contractor)</b>	N/A
Julie Parsons, MD	Planner, Moderator	Biogen; Genentech; Novartis; Scholar Rock <b>(All Contractor)</b>	No
Vamshi Rao, MD	Moderator	Avexis; Biogen; Capricor; Genentech; NSpharma; PTC Therapeutics, Inc.; RegenxBio; Sarepta Therapeutics, Inc.; Scholar Rock; Watermark <b>(All Contractor)</b>	No
Samuel Rosenfeld, MD	Planner, Presenter	OrthoPediatrics Corp. <b>(Contractor)</b>	No
Peter Schochet, MD	Planner	No relevant relationships with ineligible companies to disclose	N/A
Mary Schroth, MD	Planner, Medical Director	Audentes Therapeutics <b>(Contractor)</b>	No
Marisa Schwab, MD	Presenter	No relevant relationships with ineligible companies to disclose	No
Edward Smith, MD	Planner	Biogen; Genentech; Novartis <b>(All Contractor)</b>	N/A
Brian Snyder, MD, PhD	Presenter	Alcyone; OrthoPediatrics Corp. <b>(Both Contractor)</b>	No
Anne Stratton, MD	Planner	No relevant relationships with ineligible companies to disclose	N/A
Stacey Tarrant, RD, LDN	Planner	No relevant relationships with ineligible companies to disclose	N/A
Jane Taylor, MD	Planner	No relevant relationships with ineligible companies to disclose	N/A
Laura Watne, MD, RD	Planner	No relevant relationships with ineligible companies to disclose	N/A
Elanda Williams, MA	Planner	No relevant relationships with ineligible companies to disclose	N/A
Amy Xu, BS	Presenter	No relevant relationships with ineligible companies to disclose	No

*\*Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by, or on, patients. The ACCME does not consider providers of clinical services directly to patients to be commercial interests.*